Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE...
LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a...
LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage...
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or the underlying issuer Verona Pharma Plc of existing shares to which...
For filings with the FCA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity...
LONDON, June 05, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a...
News) - Verona Pharma PLC on Monday said it has started a clinical pharmacokinetic trial in the US for its product can ...
June 5, 2017, LONDON - Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company...
Verona Pharma PLC 30 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or Verona Pharma plc the underlying...
Verona Pharma PLC 25 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or Verona Pharma PLC the underlying...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR...
LONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a...
May 23, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused...
Verona Pharma PLC 23 May 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 1. Identity of the issuer or Verona Pharma plc the underlying...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.